CRSP.US Crispr Therapeutics AG

Healthcare Biotechnology USA Stocks
42.24 USD
Close of Nov 14, 2026
41.75 63.45
Market cap
USD 4.10B
P/E
-
P/B
2.51x
ROE
-26.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRSP.US undervalued?

Graham number

The Graham number of Crispr Therapeutics AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Crispr Therapeutics AG fundamental analysis

No fundamental analysis for Crispr Therapeutics AG yet.

Crispr Therapeutics AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Crispr Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathi…

Full company profile